Provided by Tiger Trade Technology Pte. Ltd.

PRF Technologies Ltd.

2.96
-0.0620-2.05%
Post-market: 2.87-0.0900-3.04%19:53 EST
Volume:258.33K
Turnover:825.53K
Market Cap:2.32M
PE:-0.57
High:3.60
Open:3.40
Low:2.76
Close:3.02
52wk High:27.35
52wk Low:2.76
Shares:783.06K
Float Shares:747.32K
Volume Ratio:5.68
T/O Rate:34.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2179
EPS(LYR):-160.8223
ROE:-127.65%
ROA:-36.19%
PB:0.27
PE(LYR):-0.02

Loading ...

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM

Reuters
·
Yesterday

PRF Technologies Ltd trading halted, news pending

TIPRANKS
·
Yesterday

Prf Technologies Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-5

THOMSON REUTERS
·
Feb 04

PRF Technologies Announces 1-for-5 Reverse Stock Split

Reuters
·
Feb 04

PRF Technologies Unveils Patent for Micro-Climate Solar Forecasting Software

Reuters
·
Jan 20

Why PainReform Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket

Benzinga_recent_news
·
Jan 16

PainReform Ltd - Announces Corporate Name Change to Prf Technologies Ltd, Nasdaq Ticker Symbol to Remain Prfx

THOMSON REUTERS
·
Jan 16

PainReform changes name to PRF Technologies

TIPRANKS
·
Jan 16

PainReform Ltd. Changes Name to PRF Technologies Ltd

Reuters
·
Jan 16

Press Release: PainReform Ltd. Changes Name to PRF Technologies Ltd. Reflecting Expansion into Diversified Healthcare and AI-Driven Energy Platforms

Dow Jones
·
Jan 16

PainReform Reports Positive Phase I Safety Data for OcuRing-K Ocular Drug Platform

TIPRANKS
·
Jan 12

PainReform Ltd - Announces Safety Data for Ocuring™-K Development

THOMSON REUTERS
·
Jan 12

PainReform Ltd - Preclinical Studies Show Favorable Tolerability for Ocuring™-K

THOMSON REUTERS
·
Jan 12

PainReform’s OcuRing-K Platform Shows Favorable Safety in Phase I Clinical Study

Reuters
·
Jan 12

PainReform Ltd. held shareholder meeting

Reuters
·
Jan 07

DeepSolar Launches Smart TDD to Boost Global Solar Asset Due Diligence

Reuters
·
Jan 05

PainReform Confirms LayerBio Ocular Platform Can Deliver Multiple Drugs in Sustained-Release Form

Reuters
·
Dec 10, 2025

BRIEF-Painreform Commences Development For Ocuring™-K Phase II Trial

Reuters
·
Dec 02, 2025

PainReform Advances Drop-Less OcuRing-K Therapy Toward Phase II Trial

Reuters
·
Dec 02, 2025

PainReform Commences Development for Ocuring™-K Phase Ii Trial, Layerbio’s Drop-Less Sustained-Release Ocular Therapy

THOMSON REUTERS
·
Dec 02, 2025